Non Small Cell Lung Cancer - dostarlimab-gxly + TSR-022 - HAVCR2 overexpression

Association details:

Biomarker:	HAVCR2 overexpression
Cancer:	Non Small Cell Lung Cancer
Drug:	Jemperli (dostarlimab-gxly) (PD1 inhibitor) + cobolimab (TSR-022) (TIM-3 antagonist)
Direction:	Sensitive

Evidence:

Evidence Level:

Sensitive: C3 – Early Trials

Source:

SITC 2023

Title:

596 AMBER, Part 2B: a phase 1 study of cobolimab plus dostarlimab in patients with advanced/metastatic non-small cell lung cancer (NSCLC) previously treated with anti-PD(L)-1 therapy

Published date:

11/04/2023

Excerpt:

Patients with irRECIST defined partial response or stable disease (n=12) had higher baseline TIM-3 immunohistochemistry (research use only assay) levels versus patients with progressive disease (n=22; p=0.013); a similar trend was observed for ORR….Cobolimab plus dostarlimab showed early evidence of efficacy and acceptable safety in patients with advanced/metastatic NSCLC.

DOI:

http://dx.doi.org/10.1136/jitc-2023-SITC2023.0596